Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by involvement of the brain (including the optic nerves) and spinal cord. 1, 2 The disease may have either a relapsing form or a progressive form (either from onset or after a transition from the relapsing form) and most commonly occurs in women of childbearing age. 3, 4 As a result, MS is one of the leading causes of non-traumatic disability in young adults in Western countries. 5 The underlying etiology of MS remains unknown, but a number of contributing factors have been recognized to play a contributory role including genetics, infections, and other environmental exposures, all of which are hypothesized to promote an autoimmune process leading to the disease. The role in MS of vitamin D status, thought to be an environmental contributor, will be reviewed herein.
Vitamin D metabolism and synthesis "Vitamin D" actually comprises a group of related fatsoluble compounds, with vitamin D 2 (ergocalciferol) and vitamin D 3 (cholecalciferol) being the major forms. [6] [7] [8] Vitamin D 2 (ergocalciferol) is primarily manufactured. Vitamin D 3 (cholecalciferol) is consumed in animal-based foods and is synthesized in humans in the skin from 7-dehydrocholesterol by a photolytic process into previtamin D which is subsequently isomerized into vitamin D 3 . 6 
Vitamin D and MS risk
The risk of developing MS in the setting of low serum levels of 25(OH)D (1 ng/mL = 2.49 nmol/L for 25(OH)D) has been suggested through a number of observational studies. Using prospective data from the US military repository of over 7 million military personnel, Munger et al. 9 11 When MR analyses were applied to the International MS Genetics Consortium study (14,498 MS cases and 24,091 healthy controls), each genetically determined 1 standard deviation lower 25(OH)D level conferred a 2.0-fold greater odds of MS. Using an instrumental variable analysis from established large GWASs in two large data sets, there was an association between low serum concentrations of vitamin D and risk of pediatric-onset MS after adjusting for sex, ancestry, HLA-DRB1*15:01, and over 100 non-human leukocyte antigen (HLA) MS risk variants. 12 Epidemiologic trends provide evidence that genetics have a contributory role to the development of MS given the up to 15-fold increased risk to first-degree relatives. 13 One of the strongest contributors to susceptibility to MS is associated with genes of the major histocompatibility complex (MHC), particularly HLA-DRB1. 14 A vitamin D response element (VDRE) localizes to the promoter region of HLA-DRB1, and functional studies found increased genetic expression when exposed to 1,25-dihydroxyvitamin D 3 . 15 In separate work, Ramagopalan et al. 16 performed whole exome sequencing of 43 individuals from families with multiple members with MS and identified rare variant in the CYP27B1 gene, which is involved in vitamin D metabolism and is associated with vitamin D-dependent rickets when there is homozygous loss of function. Further genotyping in >12,500 individuals showed that other rare loss of function CYP27B1 variants also conferred significant risk of MS. These findings suggest a biologically plausible relationship between an established genetic risk factor and a known environmental risk factor for MS.
Vitamin D and MS disease activity
Vitamin D status is not only associated with risk and onset of MS but it also appears to have a role in modulating the degree of disease activity. Many investigations in MS have used magnetic resonance imaging (MRI) as a marker of disease activity due to its strong correlation with underlying disease activity and future disability as well as the objectivity of the measure. 17, 18 In a secondary analyses including up to 2 years of follow-up of participants in the BENEFIT trial, gadolinium-enhancing lesion development was inversely associated with 25(OH)D levels; those whose 25(OH) D levels were ≥50 nmol/L had a 39% lower risk of new gadolinium-enhancing lesions. 5 A prospective 2-year study examined the relationship between vitamin D and disease activity in relapsing-remitting multiple sclerosis (RRMS) prior to and after starting treatment with interferon β-1a (IFN-β-1a). 19 While the study found that increasing levels of 25(OH)D were associated with a significant lower number of active MRI scans in untreated patients with MS, there was no association between the 25(OH)D levels and MRI activity after starting IFN-β therapy.
The EPIC 5-year MS cohort study included 469 subjects with either relapsing MS or clinically isolated syndrome (CIS) who underwent over 2300 MRIs. 20 The study revealed an association between vitamin D levels and MRI activity; each 10 ng/mL higher vitamin D level was associated with a 15% lower risk of later new T2-weighted lesions and about a one-third reduction in the risk of new gadolinium-enhancing lesions. Among participants in the Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND) study, 21 with an average follow-up of 2 years, participants with higher serum 25(OH)D levels during the first 12 months had lower numbers of new and contrast-enhancing lesions. A 50-nmol/L higher serum 25(OH)D level was associated with a 31% lower rate of new lesions, and those with 25(OH)D levels ≥100.0 nmol/L had a 47% lower rate of new T2 lesions and new gadolinium-enhancing lesions when compared to patients who had serum levels of 50.0-74.9 nmol/L. Vitamin D may also have an association with gray matter volume loss in MS. In an analysis of a subgroup of patients in the phase 2 CIS trial STAyCIS (atorvastatin vs placebo), 25(OH)D levels showed an inverse relationship with gray matter volume loss, with each 25 nmol/L higher 25-hydroxyvitamin level being associated with 7.8 mL higher gray matter volume. 22 There were also non-statistically significant trends between average vitamin D level and inflammatory disease activity (>3 new T2 lesions or >1 relapse in a year).
The Southern Tasmanian MS Longitudinal Study was a prospective longitudinal cohort study that evaluated the role of personal UV radiation (UVR) exposure and 25(OH)D on the clinical course of MS. 23 The participants had a lower risk of relapse with increasing 25(OH)D levels. When accounting for age-and sexadjusted hazard ratio for relapse, each 10 nmol/L greater 25(OH)D was associated with a 9% (95% confidence interval (CI): 3%-15%) lower risk of relapse. This association appeared to hold true regardless of age. In a two-center longitudinal study of patients with pediatric-onset MS or CIS, seasonally adjusted 25(OH)D level was also inversely associated with relapse rate. 24 Specifically, for every 10 ng/mL higher adjusted 25-hydroxyvitamin D 3 level, the risk of subsequent relapses decreased by 34%.
In addition to relapse rate and MRI activity, several groups have found a suggestion that vitamin D status may impact disability. In the previously mentioned European Prospective Investigation into Cancer and Nutrition (EPIC) study, 20 each 10 ng/mL higher vitamin D level was associated with lower subsequent disability as assessed by the Expanded Disability Status Scale (EDSS) (0.047; 95% CI: 0.091-0.003; p = 0.037). Another group investigated a cohort of MS patients in the Netherlands and found a negative correlation between 25(OH)D levels and disability scores. 25 In a case-control study from China, multivariate analyses using dichotomous 25(OH)D levels, values less than or equal to 20 ng/mL indicted the MS high progression. 26 
Completed trials
Several small preliminary studies (the first in 1986 27 ) have been published with mixed findings. In a study designed to assess vitamin D 3 supplementation's effects on bone mineral density in MS, Kampman et al. 28 reported that after 96 weeks of 20,000 IU weekly of vitamin D 3 , there was no clear effect on secondary outcomes such as MS activity with respect to relapse rate, functional tests, or fatigue severity. Stein et al. 29 performed a randomized trial of high-dose vitamin D 2 (n = 15, titrated to goal 25(OH)D levels of 130-175 nmol/L) versus vitamin D 3 1000 IU/day in relapsing MS and found no effect on imaging or clinical outcomes. Mosayebi and colleagues investigated the short-term effect of high-dose vitamin D 3 300,000 IU/month versus placebo on EDSS and MRI markers of disease activity. After 6 months, there were no significant differences in average of the mean number of gadolinium-enhancing lesions or change in EDSS. For all of these studies, there are many reasons that vitamin D did not appear to have a therapeutic effect: it may well be that vitamin D supplementation is not only helpful, but it is also possible that the dosages studied were not sufficient, the sample sizes were too small, or that other study characteristics (patients chosen, length of study) did not allow for detecting a treatment effect.
A few studies have demonstrated an effect of vitamin D supplementation on secondary outcomes that measured MS disease activity. Kimball et al. 30 performed a 6-month safety study with escalating doses of vitamin D. While not the primary endpoint, there was a significant reduction in the mean number of gadolinium-enhancing lesions at the end of the study. The Finnish Vitamin D Study was a randomized, doubleblind, placebo-controlled trial examining the safety of 20,000 IU weekly vitamin D 3 . 31 At the end of the 1-year study, there were no clinical significant differences, but the vitamin D 3 (add-on treatment to IFN-β) group had a significantly lower number of gadolinium-enhancing lesions on brain MR. Burton et al. 32 performed a 52-week safety study with escalating doses of vitamin D 3 3 up to 40,000 IU/day, which resulted in a mean peak 25(OH)D concentration of 413 nmol/L. The study was unblinded, with exploratory clinical endpoints that revealed that among trial completers, the proportion of treated patients suffering a relapse was lower than the control group at 0.16 versus 0.37 (McNemar, p = 0.09).
The double-blind, multicenter, 48-week SOLAR study of high-dose oral cholecalciferol has been the largest study to date. 33 The study randomized 229 participants to receive either daily oral cholecalciferol (14,000 IU vitamin D 3 ) or placebo as add-on therapy to 44-µg scIFN β-1a. The primary endpoint was proportion of subjects without evidence of disease activity (or disease activity free (DAF)) at week 48. DAF was defined as lack of progression in EDSS, lack of new MRI lesions, and absence of relapse. There were no statistically significant differences in DAF between the treatment and placebo groups. There was an insignificant trend toward lower annualize relapse rate in the treatment group with ARRs of 0.28 in vitamin D group versus 0.41 in placebo (p = 0.17) Vitamin D 3 was also associated with a statistically significant reduction in combined unique lesions at 48 weeks (secondary endpoint).
The CHOLINE study investigated the addition of vitamin D 3 100,000 IU every other week (n = 63) or placebo (n = 66) to IFN-β-1a over 96 weeks. 34 There was a non-significant trend toward a lower annualized relapse rate, the primary endpoint, among those receiving vitamin D treatment, which became statistically significant when the analysis was restricted to those who completed the study. Among completers, there were also significantly fewer new T2 lesions in the vitamin D group.
It is unclear whether these trials' mixed findings are related to insufficient power or other study-related issues leading to inability to detect a treatment effect for all outcomes or whether the "positive" findings for some secondary outcomes represent chance. A number of larger randomized control trials are currently underway to help elucidate the role of vitamin D supplementation as an add-on to IFN-β therapy in the treatment of CIS and relapsing MS. These studies include the VITADEM study in Spain, the EVIDIMS study in Germany, the PrevANZ study in Australia, and the D-Lay-MS study in France. In the United States, the multicenter Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial is assessing vitamin D 3 5000 IU/day versus 600 IU/day as add-on to glatiramer acetate.
Safety of vitamin D supplementation in MS
In Burton et al., 32 despite reaching 25(OH)D levels far greater than the toxic threshold of 250 nmol/L for 18 weeks, there were no reported adverse events. Similarly, in Kimball et al.'s 30 study, after 28 weeks of increasing doses of vitamin D 3 (ranging from 28,000 to 280,000 IU/week) patients had a significant elevation of serum vitamin D to 386 ± 157 nmol/L. Despite these supraphysiologic levels, the medication was well tolerated. There was no significant change in the calcemic response (serum calcium concentrations and the urinary ratio of calcium to creatinine). Moreover, liver enzymes, serum creatinine, electrolytes, serum protein, and parathyroid hormone remained unchanged. It should be cautioned that these safety studies were of limited duration and not designed to evaluate the long-term effects of such high-dose supplementation.
Vitamin D supplementation: what should people with MS do?
The Institute of Medicine (IOM) Dietary Reference Intakes for Calcium and Vitamin D suggests 600 IU of vitamin D daily for people up to age 70. 35 Considering current evidence, many practitioners question whether people with MS should empirically be supplemented while awaiting for more conclusive results of vitamin D clinical trials. At our center, we generally make decisions on a case-by-case basis when considering potential adverse in those at risk of excess vitamin D. Since our prior research 36 has shown that lower dose (≤800 IU/day) cholecalciferol supplementation did not have a significant increase in MS patients' 25(OH)D levels and because we generally aim for goal 25(OH)D levels between 40 and 60 ng/mL (100-150 nmol/L), most of our patients take between 2000 and 5000 IU/day vitamin D. 3 After starting supplementation, we recommend measuring the level after 3 months to further tailor the dose, as MS patients may have a less robust response to supplementation compared to those without comorbidities. 37 
Conclusion
This review provides evidence suggesting a possible contribution of vitamin D to both the risk of developing MS and the overall disease course. As additional studies are forthcoming, more evidence is required before we can conclusively determine the role of vitamin D supplementation in established MS. Given its favorable safety profile, off-label vitamin D supplementation on a case-by-case basis may be reasonable.
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